Lamivudine

Sold as Tc, Cipla lamivudine, Bio-lamivudine, Adco-lamivudine, Lavos, Pharma-q lamivudine, Bindolam, Hetlam, Aspen lamivudine, Ap lamivudine, Adco lamivudine, Retlam, Qulam, Macleods lamivudine, Medpro-lamivudine, Lazena, Lamivudine SPEC, Lamivudine winthrop, Lamivudine teva, Lamivudine sandoz, Lamileod, Vari-lamivudine, Sonke lamivudine, Legram

C₈H₁₁N₃O₃S229.26 g/mol

4-Amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one

Drag to rotate. Structure from PubChem CID 60825.

Loading Wikipedia summary

Registration

Applicants: 19
Registrations: 35
Schedule source: Consolidated Schedules 06 July 2026

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Glaxosmithkline South Africa (Pty) Limited1 of 2 cancelled	Tc	3	300366, 300367	S4	None
Cipla Medpro (Pty) LtdCancelled	Cipla lamivudine	oral solution, 300	350248, 370615, 410140	S4	None
Biotech Laboratories (Pty) Ltd	Bio-lamivudine, Lavos	150, solution	410229, 410308	S4	None
Adcock ingram limited2 of 5 cancelled	Adco-lamivudine, Adco lamivudine, Retlam, Lavos	10 mg/ml, 150 mg, 300 mg	410236, 410331, 440294, 440295, 440296	S4	PI PIL
Pharma-q Holdings (Pty) Ltd	Pharma-q lamivudine	syrup	420565	S4	None
Aurobindo Pharma (Pty) Ltd	Bindolam	10 mg/ml	421093	S4	None
Hetero Drugs South Africa (Pty) Ltd	Hetlam	oral solution	430831, 510096	S4	None
Pharmacare limited û woodmead	Aspen lamivudine, Ap lamivudine	150 mg, 300 mg, syrup	430832, 431102, A380357	S4	None
Macleods Pharmaceuticals SA (Pty) Ltd	Qulam, Macleods lamivudine, Lamileod	10 mg, 150	440703, 450538, 610316	S4	PIL
Medpro Pharmaceutica (Pty) LtdCancelled	Medpro-lamivudine	30 mg	450767	S4	None
Viatris Healthcare (Pty) Ltd	Lazena	150, 300	460010, 460011	S4	None
Specpharm (Pty) LtdCancelled	Lamivudine SPEC	150 mg	460629	S4	None
Zentiva South Africa (Pty) Ltd	Lamivudine winthrop	150 mg	460760	S4	None
Teva Pharmaceuticals (Pty) LtdCancelled	Lamivudine teva	150, 300	480049, 480050	S4	None
Winthrop Pharmaceuticals (Pty) Ltd	Lamivudine winthrop	300 mg	480174	S4	None
Sandoz South Africa (Pty) Ltd	Lamivudine sandoz	Not stated	490374	S4	None
Lebasi Pharmaceuticals (Pty) LtdCancelled	Vari-lamivudine	150 mg	A390610	S4	None
Ranbaxy (SA) (Pty) LtdCertificate held by Ranbaxy Pharmaceuticals (Pty) Ltd	Sonke lamivudine	150 mg	A400272	S4	PI PIL
Novagen Pharma (Pty) Ltd1 of 2 cancelled	Legram	10 mg/ml, 150 mg	A400376, A400561	S4	None

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
3 tc tablets EACH TABLET CONTAINS LAMIVUDINE 150 mg	3Tablets	30036630/20.2.8/0366	Registered	S4	None
3 tc oral solution EACH 1 ml SOLUTION CONTAINS LAMIVUDINE 10,0 mg	3Oral solution	30036730/20.2.8/0367	Cancelled	S4	None
Cipla lamivudine EACH TABLET COTAINS LAMIVUDINE 150,0 mg	Not listed	35024835/20.2.8/0248	Cancelled	S4	None
Cipla lamivudine oral solution EACH 5,0 ml SOLUTION CONTAINS LAMIVUDINE 50,0 mg	Oral solution	37061537/20.2.8/0615	Cancelled	S4	None
Cipla lamivudine 300 EACH TABLET CONTAINS LAMIVUDINE 300,0 mg	300	41014041/20.2.8/0140	Cancelled	S4	None
Bio-lamivudine 150 EACH TABLET CONTAINS LAMIVUDINE 150,0 mg	150	41022941/20.2.8/0229	Registered	S4	None
Adco-lamivudine tablets EACH TABLET CONTAINS :LAMIVUDINE 150,0 mg	150 mgFilm-coated tablets	41023641/20.2.8/0236Approved 4 January 2022	Registered	S4	PI PIL
Lavos solution EACH 1,0 ml SOLUTION CONTAINS LAMIVUDINE 10,0 mg	Solution	41030841/20.2.8/0308	Registered	S4	None
Adco-lamivudine solution EACH 1,0 ml SOLUTION CONTAINS: LAMIVUDINE 10,0 mg	10 mg/mlSolution	41033141/20.2.8/0331Approved 9 May 2022	Registered	S4	PI PIL
Pharma-q lamivudine syrup EACH 1,0 ml SYRUP CONTAINS LAMIVUDINE 10,0 mg	Syrup	42056542/20.2.8/0565	Registered	S4	None
Bindolam oral solution 10 mg/ml EACH 1,0 ml SOLUTION CONTAINS LAMIVUDINE 10,0 mg	10 mg/mlOral solution	42109342/20.2.8/1093	Registered	S4	None
Hetlam EACH TABLET CONTAINS LAMIVUDINE 150,0 mg	Not listed	43083143/20.2.8/0831	Registered	S4	None
Aspen lamivudine 300 MG EACH TABLET CONTAINS LAMIVUDINE 300,0 mg	300 mg	43083243/20.2.8/0832	Registered	S4	None
Ap lamivudine 150 MG EACH TABLET CONTAINS LAMIVUDINE 150,0 mg	150 mg	43110243/20.2.8/1102	Registered	S4	None
Adco lamivudine 300 MG tablet EACH TABLET CONTAINS LAMIVUDINE 300,0 mg	300 mgTablet	44029444/20.2.8/0294	Registered	S4	None
Retlam 300 MG tablet EACH TABLET CONTAINS LAMIVUDINE 300,0 mg	300 mgTablet	44029544/20.2.8/0295	Cancelled	S4	None
Lavos 300 MG tablet EACH TABLET CONTAINS LAMIVUDINE 300,0 mg	300 mgTablet	44029644/20.2.8/0296	Cancelled	S4	None
Qulam 150 EACH TABLET CONTAINS LAMIVUDINE 150,0 mg	150	44070344/20.2.8/0703	Registered	S4	None
Macleods lamivudine 150 EACH TABLET CONTAINS LAMIVUDINE 150,0 mg	150	45053845/20.2.8/0538	Registered	S4	None
Medpro-lamivudine 30 MG EACH TABLET CONTAINS LAMIVUDINE 30,0 mg	30 mg	45076745/20.2.8/0767	Cancelled	S4	None
Lazena 150 EACH TABLET CONTAINS LAMIVUDINE 150,0 mg	150	46001046/20.2.8/0010	Registered	S4	None
Lazena 300 EACH TABLET CONTAINS LAMIVUDINE 300,0 mg	300	46001146/20.2.8/0011	Registered	S4	None
Lamivudine 150 MG SPEC EACH TABLET CONTAINS LAMIVUDINE 150,0 mg	150 mg	46062946/20.2.8/0629	Cancelled	S4	None
Lamivudine winthrop 150 MG EACH TABLET CONTAINS LAMIVUDINE 150,0 mg	150 mg	46076046/20.2.8/0760	Registered	S4	None
Lamivudine teva 150 EACH TABLET CONTAINS LAMIVUDINE 150,0 mg	150	48004948/20.2.8/0049	Cancelled	S4	None
Lamivudine teva 300 EACH TABLET CONTAINS LAMIVUDINE 300,0 mg	300	48005048/20.2.8/0050	Cancelled	S4	None
Lamivudine winthrop 300 MG EACH TABLET CONTAINS LAMIVUDINE 300,0 mg	300 mg	48017448/20.2.8/0174	Registered	S4	None
Lamivudine sandoz EACH TABLET CONTAINS LAMIVUDINE 300,0 mg	Not listed	49037449/20.2.8/0374	Registered	S4	None
Hetlam oral solution EACH 1,0 ml SOLUTION CONTAINS LAMIVUDINE 10,0 mg	Oral solution	51009651/20.2.8/0096	Registered	S4	None
Lamileod 10 mg/ml EACH 1,0 ml SOLUTION CONTAINS: LAMIVUDINE 10,0 mg	10 mgOral solution	61031661/20.2.8/0316Approved 28 July 2026	Registered	S4	PIL
Aspen lamivudine syrup EACH 1,0 ml SYRUP CONTAINS LAMIVUDINE 10,0 mg	Syrup	A380357A38/20.2.8/0357	Registered	S4	None
Vari-lamivudine 150 MG EACH TABLET CONTAINS LAMIVUDINE 150,0 mg	150 mg	A390610A39/20.2.8/0610	Cancelled	S4	None
Sonke lamivudine 150 EACH TABLET CONTAINS: LAMIVUDINE 150,0 mg	150 mgFilm- coated tablets	A400272A40/20.2.8/0272Approved 25 January 2023	Registered	S4	PI PIL
Legram 150 MG tablets EACH TABLET CONTAINS LAMIVUDINE 150,0 mg	150 mgTablets	A400376A40/20.2.8/0376	Registered	S4	None
Legram 10 mg/ml oral solution EACH 1,0 ml SOLUTION CONTAINS LAMIVUDINE 10,0 mg	10 mg/mlOral solution	A400561A40/20.2.8/0561	Cancelled	S4	None

Regulatory status

Where S4 sits on the scale

S0S1S2S3S4S5S6S7S8

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Lamivudine

S4: Lamivudine
Consolidated Schedules 06 July 2026, line 6850

Pharmacological class: Antiviral agents. (class 20.2.8)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

Adco-lamivudine tablets, Adcock ingram limited is scheduled S4 in its official SAHPRA documents, read with 90% confidence.

Professional information (PI)For healthcare professionalsAdco-lamivudine tablets, Adcock ingram limited Patient information leaflet (PIL)For patients and carersAdco-lamivudine tablets, Adcock ingram limited

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles

Background